(Reuters) – The U.S. Food and Drug Administration on Friday approved Amgen Inc’s biosimilar copy of Johnson & Johnson’s blockbuster rheumatoid arthritis drug, Remicade, according to the regulator’s website. FILE PHOTO: An Amgen sign is seen at the company’s office in South San Francisco, California October 21, 2013. REUTERS/Robert Galbraith […]